Lobos-Bejarano José María, del Castillo-Rodríguez José Carlos, Mena-González Amparo, Alemán-Sánchez José J, Cabrera de León Antonio, Barón-Esquivias Gonzalo, Pastor-Fuentes Agustín
Centro de Salud Jazmín, Área Este, Atención Primaria, Madrid, España.
Med Clin (Barc). 2013 Oct 5;141(7):279-86. doi: 10.1016/j.medcli.2012.12.023. Epub 2013 May 15.
The main therapeutic objective in atrial fibrillation (AF) patients is stroke prevention. This study is aimed to determine whether the anticoagulant therapy may be appropriate regarding to the Guidelines and patients' profile in primary healthcare in Spain.
A national, multicenter, cross-sectional study of AF patients attended in primary healthcare in Spain has been conducted. The study involved 185 family physicians whose patients were randomized.
A total of 3,759 AF patients were randomized from the clinical records, and 2,070 were included in the study, at an average age of 74 (11) years old (50.7% female). Most of them (78%) had permanent AF and high comorbidity rates (hypertension 75%, obesity 30%, diabetes 27%, heart failure 20%, coronary heart disease 17%, and social risk 15%). Patients diagnosed in primary healthcare were more frequently asymptomatic than in hospital setting (36%; P<.001). The therapeutic strategy was based on the heart rate control in 4 out of 5 patients. Anticoagulation therapy was widely used (84%), more frequently in patients with permanent vs. non-permanent AF (91 vs. 60%, P<.001). Follow-up and monitoring was mainly performed in primary care (72%). The anticoagulation control was suboptimal, with a 66% of the international normalized ratio (INR) in therapeutic range, dropping to 33% when the last 3 available INR were included (P<.001).
A high rate of patients with anticoagulant therapy in primary healthcare has been found in this research. INR control, however, remains suboptimal. Heart rate control is the most commonly used strategy. The decision about the anticoagulation should be based on the thromboembolic risk rather than in the arrhytmia type.
心房颤动(AF)患者的主要治疗目标是预防中风。本研究旨在确定在西班牙初级医疗保健中,抗凝治疗是否符合指南及患者情况。
对西班牙初级医疗保健中诊治的AF患者进行了一项全国性、多中心横断面研究。该研究涉及185名家庭医生,其患者被随机分组。
从临床记录中随机抽取了3759例AF患者,其中2070例纳入研究,平均年龄74(11)岁(女性占50.7%)。他们中大多数(78%)患有永久性AF且合并症发生率高(高血压75%、肥胖30%、糖尿病27%、心力衰竭20%、冠心病17%、社会风险15%)。在初级医疗保健中诊断出的患者比在医院环境中更常无症状(36%;P<0.001)。五分之四的患者治疗策略基于心率控制。抗凝治疗广泛应用(84%),永久性AF患者比非永久性AF患者更常使用(91%对60%,P<0.001)。随访和监测主要在初级保健中进行(72%)。抗凝控制不理想,国际标准化比值(INR)在治疗范围内的占66%,纳入最后3次可用INR时降至33%(P<0.001)。
本研究发现初级医疗保健中抗凝治疗的患者比例很高。然而,INR控制仍不理想。心率控制是最常用的策略。抗凝决策应基于血栓栓塞风险而非心律失常类型。